Protagonist Therapeutics (PTGX) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed TG Therapeutics (TGTX) over the past year, gaining 114.4% versus a gain of 58.3%. Over five years, PTGX leads with a +364.1% price change compared with +66.2% for TGTX. Protagonist Therapeutics is the larger company by market cap ($9.30 billion vs $8.48 billion), about 1.1 times the size, while TG Therapeutics is growing revenue faster (+87.3% vs -89.4%).
On valuation, TG Therapeutics trades at a lower trailing P/E (20.1x vs 139.5x for Protagonist Therapeutics). TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTGX | TGTX |
|---|---|---|
| Share price | $143.73 | $55.37 |
| Market cap | $9.30B | $8.48B |
| 1-day change | +2.73% | +3.81% |
| YTD return | +64.56% | +85.74% |
| 1-year return | +114.39% | +58.34% |
| 5-year return | +364.09% | +66.23% |
| P/E ratio (TTM) | 139.54 | 20.13 |
| Forward P/E | — | 20.45 |
| EPS (TTM) | $1.03 | $2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $46.02M | $616.29M |
| Revenue growth (YoY) | -89.41% | +87.32% |
| Net income (latest FY) | $-130.15M | $447.18M |
| Gross margin | — | 83.66% |
| Operating margin | -343.63% | 20.01% |
| Net margin | -282.83% | 72.56% |
| 52-week high | $160.81 | $59.30 |
| 52-week low | $73.08 | $26.76 |
| Distance from 52-week high | -10.62% | -6.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +21.54% | +25.90% |
| Average volume | 618.39K | 2.02M |
| Shares outstanding | 64.71M | 153.08M |
| Employees | 141 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed TGTX by 56.1 percentage points over the past year.
- Protagonist Therapeutics trades at a higher earnings multiple (139.5x vs 20.1x trailing P/E).
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs -89.41%).
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
PTGX vs TGTX FAQ
Which is bigger, Protagonist Therapeutics or TG Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $9.30B compared with $8.48B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, PTGX or TGTX?
PTGX returned +114.39% over the past 12 months, compared with +58.34% for TGTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PTGX or TGTX?
TGTX has the lower trailing P/E at 20.1, versus 139.5 for PTGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Protagonist Therapeutics and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.